Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Part I: The Endocannabinoid System, Mechanisms of Action and Functions

The pharmacology of cannabinoid receptors and their ligands: an overview

Abstract

Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB1 receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these ‘endocannabinoids’ was arachidonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. ‘Neutral’ cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance ‘autoprotective’ effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed ‘autoimpairing’ effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202.

    Article  CAS  Google Scholar 

  2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TT . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561–564.

    Article  CAS  Google Scholar 

  3. Munro S, Thomas KL, Abu-Shaar M . Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.

    Article  CAS  Google Scholar 

  4. Mu J, Zhuang S-Y, Kirby MT, Hampson RE, Deadwyler SA . Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 1999; 291: 893–902.

    CAS  PubMed  Google Scholar 

  5. Pertwee RG . Pharmacological actions of cannabinoids. In: Pertwee RG (ed) Cannabinoids. Handbook of Experimental Pharmacology. Springer-Verlag: Heidelberg, 2005, pp 1–51.

    Google Scholar 

  6. Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R . Evidence that (–)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 2005; 48: 1139–1146.

    Article  CAS  Google Scholar 

  7. Berry EM, Mechoulam R . Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95: 185–190.

    Article  CAS  Google Scholar 

  8. Pertwee RG . Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569–611.

    Article  CAS  Google Scholar 

  9. Pertwee RG . Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2004; 2: 9–29.

    Article  CAS  Google Scholar 

  10. De Petrocellis L, Cascio MG, Di Marzo V . The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765–774.

    Article  CAS  Google Scholar 

  11. Pertwee RG, Ross RA . Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101–121.

    Article  CAS  Google Scholar 

  12. Pertwee RG . Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: 165–174.

    Article  CAS  Google Scholar 

  13. Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020–1024.

    Article  CAS  Google Scholar 

  14. Pertwee RG . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129–180.

    CAS  Google Scholar 

  15. Sim-Selley LJ . Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91–119.

    Article  CAS  Google Scholar 

  16. Massi P, Patrini G, Rubino T, Fuzio D, Parolaro D . Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. Pharmacol Biochem Behav 1997; 58: 73–78.

    Article  CAS  Google Scholar 

  17. Bouaboula M, Dussossoy D, Casellas P . Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528: implications for receptor biological responses. J Biol Chem 1999; 274: 20397–20405.

    Article  CAS  Google Scholar 

  18. Pertwee RG . Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307–1324.

    Article  CAS  Google Scholar 

  19. Pan X, Ikeda SR, Lewis DL . SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 1998; 54: 1064–1072.

    Article  CAS  Google Scholar 

  20. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT . An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 2003; 140: 1451–1459.

    Article  CAS  Google Scholar 

  21. Breivogel CS, Griffin G, Di Marzo V, Martin BR . Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155–163.

    Article  CAS  Google Scholar 

  22. Guzmán M . Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745–755.

    Article  Google Scholar 

  23. Tomida I, Pertwee RG, Azuara-Blanco A . Cannabinoids and glaucoma. Br J Ophthalmol 2004; 88: 708–713.

    Article  CAS  Google Scholar 

  24. Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F . Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids 2002; 121: 191–200.

    Article  CAS  Google Scholar 

  25. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.

    Article  CAS  Google Scholar 

  26. Després J-P, Golay A, Sjöström L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.

    Article  Google Scholar 

  27. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM . Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004; 141: 1118–1130.

    Article  CAS  Google Scholar 

  28. Baker CL, McDougall JJ . The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004; 142: 1361–1367.

    Article  CAS  Google Scholar 

  29. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005; 68: 1484–1495.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R G Pertwee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pertwee, R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30 (Suppl 1), S13–S18 (2006). https://doi.org/10.1038/sj.ijo.0803272

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803272

Keywords

This article is cited by

Search

Quick links